Close Menu

NEW YORK (GenomeWeb) – A research group in Maputo, Mozambique has evaluated a prototype HIV viral load assay from Alere and shown that, while point-of-care testing is tantalizingly feasible, the particular assay is not yet ready for clinical use.

The study was based on an early prototype of the test and Alere has already made significant additional developments, a spokesperson at Alere emphasized in an email to GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

In Nature this week: the largest known collection of human genetic variants, and more.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.